Q1 2024 · 13F-HR
BML Capital Management, LLCholdings as filed
Filed 2024-04-23 · accession 0001754960-24-000175
$149.4M
Reported value
30
Positions
2024-03-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 46436E718 | SGOV | ISHARES TR | $27.2M | 18.2% | 270,000 | Common | NONE |
| 04683R106 | AVIR | ATEA PHARMACEUTICALS INC | $22.4M | 15.0% | 5,536,710 | Common | NONE |
| 78468R663 | BIL | SPDR SER TR | $18.4M | 12.3% | 200,000 | Common | NONE |
| 00773U207 | AVU0 | ADVERUM BIOTECHNOLOGIES INC | $11.8M | 7.89% | 833,117 | Common | NONE |
| 00461U105 | ACRS | ACLARIS THERAPEUTICS INC | $11.7M | 7.80% | 9,395,934 | Common | NONE |
| 23284P103 | — | CYTEIR THERAPEUTICS INC | $11.0M | 7.36% | 3,654,053 | Common | NONE |
| 28658R106 | CLYM | ELIEM THERAPEUTICS INC | $6.0M | 4.02% | 2,193,742 | Common | NONE |
| 05455M100 | — | AVROBIO INC | $5.1M | 3.43% | 4,001,627 | Common | NONE |
| 45783C200 | TIL | INSTIL BIO INC | $3.8M | 2.52% | 348,735 | Common | NONE |
| 75974E103 | — | RENEO PHARMACEUTICALS INC | $3.6M | 2.42% | 2,177,913 | Common | NONE |
| 207523101 | — | CONNECT BIOPHARMA HLDGS LTD | $3.6M | 2.40% | 2,061,338 | Common | NONE |
| 25056L103 | DSGN | DESIGN THERAPEUTICS INC | $3.5M | 2.37% | 879,478 | Common | NONE |
| 04746L104 | — | ATHIRA PHARMA INC | $2.5M | 1.65% | 900,000 | Common | NONE |
| 68403P203 | ORMP | ORAMED PHARMACEUTICALS INC | $2.5M | 1.65% | 844,496 | Common | NONE |
| 69353Y103 | PMVP | PMV PHARMACEUTICALS INC | $2.2M | 1.49% | 1,306,490 | Common | NONE |
| 046484309 | ASTC | ASTROTECH CORP | $2.0M | 1.32% | 220,410 | Common | NONE |
| 52635N103 | LENZ | LENZ THERAPEUTICS INC | $1.4M | 0.96% | 63,916 | Common | NONE |
| 49705R105 | KNTEUSD | KINNATE BIOPHARMA INC | $1.3M | 0.89% | 498,851 | Common | NONE |
| 00211Y506 | ABIOEUR | ARCA BIOPHARMA INC | $1.2M | 0.83% | 706,930 | Common | NONE |
| 34962G109 | TOCAEUR | FORTE BIOSCIENCES INC | $1.2M | 0.82% | 1,761,702 | Common | NONE |
| 59935V107 | MIST | MILESTONE PHARMACEUTICALS IN | $1.1M | 0.73% | 606,145 | Common | NONE |
| 92511W108 | — | VERRICA PHARMACEUTICALS INC | $1.1M | 0.71% | 180,000 | Common | NONE |
| 128058302 | LSTA | LISATA THERAPEUTICS INC | $888,167 | 0.59% | 284,669 | Common | NONE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $881,259 | 0.59% | 50,100 | Common | NONE |
| 92840H400 | VTGN | VISTAGEN THERAPEUTICS INC | $792,000 | 0.53% | 150,000 | Common | NONE |
| 65343E108 | NXTCEUR | NEXTCURE INC | $683,417 | 0.46% | 306,465 | Common | NONE |
| 38942Q202 | CALC | CALCIMEDICA INC | $667,364 | 0.45% | 160,424 | Common | NONE |
| 746964105 | QTTB | Q32 BIO INC | $424,194 | 0.28% | 24,894 | Common | NONE |
| 87424L207 | TLIS | TALIS BIOMEDICAL CORP | $374,001 | 0.25% | 42,743 | Common | NONE |
| 019818103 | — | ALLOVIR INC | $151,330 | 0.10% | 200,464 | Common | NONE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.